Correction to: pexidartinib: first approval
YN Lamb - Drugs, 2020 - Springer
Correction to: Pexidartinib: First Approval | Drugs Skip to main content SpringerLink Account
Menu Find a journal Publish with us Search Cart 1.Home 2.Drugs 3.Article Correction to …
Menu Find a journal Publish with us Search Cart 1.Home 2.Drugs 3.Article Correction to …
Abstract A080: A phase 1 study of single-agent pexidartinib in Asian patients with advanced solid tumors (NCT02734433)
CC Lin, JH Lee, CH Hsu, WW Chen, YH Yen… - Molecular Cancer …, 2018 - AACR
Background: Pexidartinib is a novel, orally active, small-molecule kinase inhibitor that
selectively targets the colony-stimulating factor-1 receptor (CSF1R), as well as the receptors …
selectively targets the colony-stimulating factor-1 receptor (CSF1R), as well as the receptors …
Results from phase I extension study assessing pexidartinib treatment in six cohorts with solid tumors including TGCT, and abnormal CSF1 transcripts in TGCT
WD Tap, AS Singh, SP Anthony, M Sterba… - Clinical Cancer …, 2022 - AACR
Purpose: To assess the response to pexidartinib treatment in six cohorts of adult patients
with advanced, incurable solid tumors associated with colony-stimulating factor 1 receptor …
with advanced, incurable solid tumors associated with colony-stimulating factor 1 receptor …
Supporting patients in the transition to the revised pexidartinib dosing regimen: perspectives from the multidisciplinary clinical and allied health professional team
C McCabe, H Wright, K Polson, AJ Wagner - Orphanet Journal of Rare …, 2023 - Springer
Pexidartinib is a colony-stimulating factor-1 receptor inhibitor approved in the United States
for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) …
for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) …
Effect of mild and moderate hepatic impairment (defined by Child–Pugh classification and National Cancer Institute Organ Dysfunction Working Group criteria) on …
H Zahir, J Greenberg, C Hsu… - The Journal of …, 2022 - Wiley Online Library
Pexidartinib is a novel oral small‐molecule tyrosine kinase inhibitor targeting the colony‐
stimulating factor 1 receptor. Pexidartinib undergoes extensive hepatic metabolism via …
stimulating factor 1 receptor. Pexidartinib undergoes extensive hepatic metabolism via …
Pharmacokinetics of the Multi‐kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality
H Zahir, J Greenberg, C Hsu… - Clinical …, 2023 - Wiley Online Library
Pexidartinib is an oral small‐molecule tyrosine kinase inhibitor that selectively targets colony‐
stimulating factor 1 receptor. Two phase 1 single‐center trials were conducted in healthy …
stimulating factor 1 receptor. Two phase 1 single‐center trials were conducted in healthy …
Dosing recommendation based on the effects of different meal types on pexidartinib pharmacokinetics in healthy subjects: implementation of model‐informed drug …
H Zahir, O Yin, C Hsu, AJ Wagner… - Clinical …, 2023 - Wiley Online Library
Pexidartinib, an oral small molecule inhibitor of the colony‐stimulating factor 1 receptor, is
approved for treatment of adults with symptomatic tenosynovial giant cell tumor associated …
approved for treatment of adults with symptomatic tenosynovial giant cell tumor associated …
Population pharmacokinetic analysis of pexidartinib in healthy subjects and patients with tenosynovial giant cell tumor or other solid tumors
O Yin, AJ Wagner, J Kang, W Knebel… - The Journal of …, 2021 - Wiley Online Library
Pexidartinib is a kinase inhibitor that induces tumor response and improvements in
symptoms and functional outcomes in adult patients with symptomatic tenosynovial giant cell …
symptoms and functional outcomes in adult patients with symptomatic tenosynovial giant cell …
Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects
H Zahir, J Greenberg, D Shuster, C Hsu… - Clinical …, 2022 - Springer
Abstract Background and Objective Pexidartinib is a novel oral small-molecule inhibitor that
selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine …
selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine …
Correction to: selpercatinib: first approval
A Markham - Drugs, 2021 - Springer
Correction to: Selpercatinib: First Approval | Drugs Skip to main content SpringerLink Account
Menu Find a journal Publish with us Track your research Search Cart 1.Home 2.Drugs 3.Article …
Menu Find a journal Publish with us Track your research Search Cart 1.Home 2.Drugs 3.Article …